Product Pipeline

Candidate & Indication Development Stage
R & D Preclinical Phase 1 Phase 2 Phase 3
Iomab-B (CD45) (apamistamab-I-131) BMT conditioning1
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Iomab-ACT (CD45) (apamistamab-I-131) GeneTx and Cell therapy conditioning
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A (CD33) and CLAG-M Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A (CD33) and Venetoclax Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-A CD33 Completed
AML
Newly diagnosed patients
with AML over age 60
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Actimab-A (CD33) and Venetoclax with HMA Planned
Relapsed/Refractory AML
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-M CD33 Multiple Myeloma
penta refractory patients age 18 and above
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-MDS CD33 Planned
Myelodysplastic Syndrome (MDS)
Myeloablation prior to BMT for high-risk MDS patients
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
AWE Technology Platform Actinium-225 conjugated to daratumumab
CD38 targeting agent for multiple myeloma
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-C Colon Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-P Prostate Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Actimab-Br Brain Cancer
R & D Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  1. BMT or HSCT (Hematopoietic Stem Cell Transplantation) is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.